Corvus制药 CRVS 深 沪

电话会总结 ｜ Corvus(CRVS)2025财年Q4业绩电话会核心要点

<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>&#8226; 根据Corvus业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **研发费用：** 2025年第四季度研发费用为990万美元，全年研发费用为3,370万美元，主要用于soquelitinib的临床试验和制造成本以及人员费用增长。 **净亏损：** 2025年第四季度净亏损1,230万美元，全年净亏损数据未具体披露。亏损中包含Angel Pharmaceuticals股权投资的非现金损失70万美元。 **股权激励费用：** 2025年第四季度股权激励费用为160万美元。 **现金状况：** 截至2025年12月31日，现金、现金等价物和有价

03-16 14:29

Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q4 earnings call. Read on fo...

03-14 08:11

BUZZ-U.S. STOCKS ON THE MOVE-PayPay Corp, Ulta Beauty, InMode

BUZZ-U.S. STOCKS ON THE MOVE-PayPay Corp, Ulta Beauty, InMode Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 13 (Reuters) - Wall Street's main stock indexes were set to op

03-13 21:31

BUZZ-Biotech Corvus expands stock sale agreement with Jefferies, shares down

BUZZ-Biotech Corvus expands stock sale agreement with Jefferies, shares down ** Shares of biotech firm Corvus Pharmaceuticals CRVS.O fall 2% to $15.69 premarket ** Co expands at-the-market stock sale agreement with Jefferies for up to $200 million, doubling the prior $100 million limit set in 2024 *

03-13 20:58

Corvus Pharmaceuticals ups Jefferies ATM equity offering to USD 200 million

Corvus Pharmaceuticals ups Jefferies ATM equity offering to USD 200 million Corvus entered an amended and restated open market sale agreement with Jefferies to sell shares of its common stock from time to time. The agreement provides for sales with a maximum aggregate offering price of up to USD 200

03-13 20:47

Corvus Pharma Q4 EPS $(0.15) Misses $(0.13) Estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 16.67 percent increase over losses of $(0.18) per share from

03-13 04:01

Earnings Scheduled For March 12, 2026

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...

03-12 19:11

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

03-05 21:01

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its leadership team will present a corporate overview at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40pm ET. A live webcast of the presentation will be available, along with a replay for 90 days post-event. The company, focused on developing ITK inhibition for various immune diseases and cancers, is highlighting its l...

02-23 21:01

美股周涨跌榜 | Corvus制药周内狂飙211.8%，特应性皮炎新药临床试验结果积极；Avino银及金矿周涨超32.8%

Corvus制药周内狂飙211.8%，特应性皮炎新药临床试验结果积极；Avino银及金矿周涨超32.8%，现货白银站上100美元>>

01-24 09:50